(SCAP) Series Portfolios Trust - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US81752T4452
SCAP: Small, Capitalization, Value, ETF
The Series Portfolios Trust (NYSE ARCA:SCAP) is an ETF that focuses on investing in small-capitalization companies, allocating at least 80% of its net assets to securities within this market segment. The fund defines small-cap companies as those with market capitalizations within or below the range of the Russell 2000 Index, providing a benchmark for its investment universe.
As a Small Value ETF, SCAP is designed to capture the performance of undervalued small-cap companies in the US market. Its investment strategy is centered around identifying companies with lower market capitalizations that have the potential for growth or are currently undervalued by the market.
Analyzing the technical data, we can observe that SCAPs last price is $31.99, slightly above its 20-day Simple Moving Average (SMA) of $31.88, indicating a potential bullish trend. The 50-day SMA is $31.30, further supporting this trend. However, the 200-day SMA at $33.45 suggests that the ETF is currently trading below its longer-term average, potentially signaling a buying opportunity. The Average True Range (ATR) of 0.47, or 1.46%, indicates moderate volatility.
From a fundamental perspective, the Assets Under Management (AUM) for SCAP stand at $13.86 million USD, a relatively modest size that could impact liquidity but also indicates a focused investment strategy. Given its small size and specific investment mandate, SCAP may appeal to investors seeking targeted exposure to small-cap value companies.
Forecasting SCAPs performance, we can anticipate that if the current bullish trend continues, with the ETF remaining above its 20-day and 50-day SMAs, it may attract more investors, potentially driving the price upwards. However, if the ETF fails to break through the resistance level around its 200-day SMA, it may face a correction. Considering the current ATR, a price movement of around 1.46% can be expected in the short term. Therefore, a potential target price could be around $32.50, representing a 1.5% increase from the current price, assuming the bullish trend persists and the ETF continues to attract investors focused on small-cap value.
Additional Sources for SCAP ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
SCAP ETF Overview
Market Cap in USD | 14m |
Category | Small Value |
TER | 0.80% |
IPO / Inception | 2023-12-11 |
SCAP ETF Ratings
Growth Rating | 24.9 |
Fundamental | - |
Dividend Rating | 73.7 |
Rel. Strength | -2.3 |
Analysts | - |
Fair Price Momentum | 39.97 USD |
Fair Price DCF | - |
SCAP Dividends
Dividend Yield 12m | 6.92% |
Yield on Cost 5y | 8.38% |
Annual Growth 5y | 420.60% |
Payout Consistency | 66.7% |
Payout Ratio | % |
SCAP Growth Ratios
Growth Correlation 3m | 42.8% |
Growth Correlation 12m | -11.7% |
Growth Correlation 5y | 58.5% |
CAGR 5y | 13.05% |
CAGR/Max DD 5y | 0.54 |
Sharpe Ratio 12m | 0.73 |
Alpha | -2.64 |
Beta | 1.019 |
Volatility | 18.63% |
Current Volume | 1.4k |
Average Volume 20d | 1.4k |
As of June 21, 2025, the stock is trading at USD 32.77 with a total of 1,392 shares traded.
Over the past week, the price has changed by +0.88%, over one month by +0.15%, over three months by +0.23% and over the past year by +7.49%.
Neither. Based on ValueRay´s Analyses, Series Portfolios Trust is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 24.94 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SCAP is around 39.97 USD . This means that SCAP is currently undervalued and has a potential upside of +21.97% (Margin of Safety).
Series Portfolios Trust has no consensus analysts rating.
According to our own proprietary Forecast Model, SCAP Series Portfolios Trust will be worth about 45.2 in June 2026. The stock is currently trading at 32.77. This means that the stock has a potential upside of +37.9%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 45.2 | 37.9% |